ASP-9831

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H23N3O3
Molecular Weight	353.4149
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCC1=CC=C2N1N=C(COC)C(CCC(O)=O)=C2C3=CC(C)=CN=C3

InChI

InChIKey=UECHVFIKTBUKTP-UHFFFAOYSA-N

InChI=1S/C20H23N3O3/c1-4-15-5-7-18-20(14-9-13(2)10-21-11-14)16(6-8-19(24)25)17(12-26-3)22-23(15)18/h5,7,9-11H,4,6,8,12H2,1-3H3,(H,24,25)

HIDE SMILES / InChI

Molecular Formula	C20H23N3O3
Molecular Weight	353.4149
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Tue Apr 01 16:56:21 GMT 2025` Edited by `admin` on `Tue Apr 01 16:56:21 GMT 2025`
Record UNII	TK9MSV53AD
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

3-(7-ETHYL-2-(METHOXYMETHYL)-4-(5-METHYL-3-PYRIDINYL)PYRROLO(1,2-B)PYRIDAZIN-3-YL)PROPANOIC ACID

Preferred Name

English

ASP-9831

Common Name

English

ASP9831

Code

English

PYRROLO(1,2-B)PYRIDAZINE-3-PROPANOIC ACID, 7-ETHYL-2-(METHOXYMETHYL)-4-(5-METHYL-3-PYRIDINYL)-

Systematic Name

English

Code System Code Type Description

SMS_ID

300000042515

Created by admin on Tue Apr 01 16:56:21 GMT 2025 , Edited by admin on Tue Apr 01 16:56:21 GMT 2025

PRIMARY

CAS

728013-50-1

Created by admin on Tue Apr 01 16:56:21 GMT 2025 , Edited by admin on Tue Apr 01 16:56:21 GMT 2025

PRIMARY

FDA UNII

TK9MSV53AD

Created by admin on Tue Apr 01 16:56:21 GMT 2025 , Edited by admin on Tue Apr 01 16:56:21 GMT 2025

PRIMARY

PUBCHEM

10360713

Created by admin on Tue Apr 01 16:56:21 GMT 2025 , Edited by admin on Tue Apr 01 16:56:21 GMT 2025

PRIMARY

Related Record Type Details


					0FY8X1RL72

CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE PDE4A1

TARGET -> INHIBITOR

Amount:

Related Record Type Details


					TK9MSV53AD

ASP-9831

ACTIVE MOIETY

Comments:

ASP9831 is a phosphodiesterase-4 inhibitor developed to treat nonalcoholic steatohepatitis (NASH). ASP9831 failed to significantly alter the biochemical markers, ALT and AST, in clinical trials. it showed potent anti-inflammatory and antifibrotic effects in preclinical studies. We evaluated the efficacy and safety of ASP9831 in patients with NASH. Despite a relevant mechanism of action, ASP9831 did not significantly alter the biochemical markers of NASH, compared with placebo, in a clinical trial. This highlights the difficulties of developing therapeutics for NASH and the need for more extensive preclinical testing of mechanisms of potential drug candidates. Clinicaltrialsregister.eu: 2005-001687-31; EudraCT numbers: 2007-002114-19.

Amount: